Allicin
Catalog No: CFN90201
Allicin exerts antioxidant, bactericidal, anti-cancer, anti-inflammatory activities, it exerts an inhibitory immunomodulatory effect on intestinal epithelial cells. Allicin could significantly inhibit vascular smooth muscle cells' proliferation and migration induced by insulin, which may be related to the inhibition of the activation of ERK signal path. Allicin is beneficial in reducing blood cholesterol, triglycerides levels and systolic blood pressure in hypercholesterolemic rats, it may beneficially affect two risk factors for atherosclerosis–hyperlipidemia and hypertension.
Telocinobufagin
Catalog No: CFN90213
Telocinobufagin is a novel endogenous digitalis, it shows a reversible local anesthetic action, similar to BUPI, however, without cardiac toxicity in vitro. Telocinobufagin has antimicrobial, potential immune system regulatory effects, it could be developed as a novel immunotherapeutic agent to treat and other immune-mediated diseases, and it may become a new immunomodulatory agent in many regions.